In past three decades, Poly Lactic-co-Glycolic Acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is an FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. Besides many appropriate characteristics, these polymers, however, have some limitations and drawbacks which limit their extensive use in formulation; potential toxicity from dose dumping, inconsistent release and drug-polymer interactions.
Key Features and Benefits of PLGA microsphere process designed by InnoCore:
- Tailored biodegradation rate (small molecules only)
- Approval for clinical use in humans by the U.S. Food and Drug Administration (FDA)
- Proprietary process to manufacture uniformly-sized microparticles
- Superior injectability due to uniformly-sized microparticles
- Reproducible and scalable microparticle production
Polyester PLGA is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA). Poly lactic acid contains an asymmetric α-carbon which is typically described as the D or L form in classical stereochemical terms and sometimes as R and S form, respectively. The enantiomeric forms of the polymer PLA are poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). PLGA is generally an acronym for poly D,L-lactic-co-glycolic acid where D- and L- lactic acid forms are in equal ratio.